Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This compound is a synthetic small molecule with the chemical formula C20H19ClN4O5 and a molecular weight of approximately 430.85 g/mol[4][7]. It belongs to the class of pyrimidinediamines and features both a benzodioxole and a trimethoxyphenyl moiety. While structurally related compounds in this series have been developed as potent inhibitors of tyrosine kinases (notably c-Src and Abl), there is no direct evidence that this specific compound has been advanced into clinical development or assigned a code name by pharmaceutical companies[1][3][7]. Its mechanism likely involves kinase inhibition due to its structural similarity to known Src/Abl inhibitors.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on N'-(5-chloro-1,3-benzodioxol-4-yl)-N-(3,4,5-trimethoxyphenyl)pyrimidine-2,4-diamine.